CAR T cells
CAR NK cells
γδ T cells
HSCs
Allogeneic cell therapies
Content
- CAR T cells
- CAR NK cells
- γδ T cells
- HSCs
- Allogeneic cell therapies
The therapeutic potential of genetically modified cells is already huge - and yet it’s waiting to be explored. With our cutting-edge technologies we help you to develop solutions from early discovery to large-scale cell manufacturing.
CAR T cells
CAR NK cells
γδ T cells
HSCs
Allogeneic cell therapies
Our solutions enable you to isolate donor T cells and to achieve efficient T cell activation, gene transfer, and expansion. Furthermore, we offer instruments, reagents, and software for functional characterization of rare CAR T cell populations.
Automate and standardize your T cell manufacturing process and safeguard your cells in a closed system setup. The CliniMACS Prodigy® T cell Transduction (TCT) and CliniMACS Prodigy T Cell Transduction – Large Scale (TCT-LS) processes integrate all steps from cell isolation, activation, and transduction to expansion and harvest of your final cell product.
With our advanced technologies for each workflow step, we at Miltenyi Biotec support CAR NK cell research and therapeutic development. Starting with enrichment of a well-defined NK cell population, we further offer optimized solutions for activation, transduction, expansion, and finally the analysis and phenotyping of engineered CAR NK cells.
Automate your CAR NK cell manufacturing process and standardize your workflow. Manufacture your cells in a closed and software-controlled environment. The CliniMACS Prodigy® NK Cell Transduction (NKCT) Process integrates all manufacturing steps from cell selection, activation, and transduction to expansion and harvest of your final cell product.
Clinical-grade natural killer (NK) cell isolation can be enabled in a two-step, fully automated manner within a closed system on the CliniMACS Prodigy. Additionally, it is possible to use the CliniMACS Prodigy for NK cell expansion or generation of engineered NK cells.
The CliniMACS Prodigy® Platform enables the automated manufacturing of γδ T cells. All processing steps – from efficient γδ T cell enrichment, activation, and expansion to optional engineering by viral transduction and final product harvest – are carried out in a closed system. The result is a robust and simplified workflow that facilitates the development of novel γδ T cell therapies.
The CliniMACS Prodigy Hematopoietic Stem Cell Engineering (HSCE) process automates manufacturing of gene-engineered hematopoietic stem cells (HSCs) by viral transduction of CD34+ cells. Manufacturing takes place in sterile and single-use tubing sets connected to the CliniMACS Prodigy Instrument, providing a functionally closed system. Its robust performance reduces donor variations while the flexible software allows for easy conversion of manual processes.
At Miltenyi Biotec, we support the entire spectrum of cell therapy modalities, empowering both autologous and allogeneic approaches whether in clinical research or commercial settings.
Our CliniMACS® Instruments, consumables, and reagents provide essential tools needed to achieve optimal growth conditions and create streamlined scalable allogeneic workflows. With flexibility built in, you can seamlessly integrate external expansion systems, such as bioreactors, to meet diverse manufacturing needs. This adaptability makes it easier to advance modalities like allogeneic stem cell therapy or allogeneic CAR T cell therapy.